Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00221494
Status:
WITHDRAWN
Last Update Posted:
2015-06-01
First Post:
2005-09-13
Brief Title:
Can Additional Drug Therapy Accelerate Response Time to Antidepressants
Sponsor:
Mark Frye
Organization:
Mayo Clinic
Study Overview
Official Title:
Can Additional Drug Therapy Accelerate Response Time to Antidepressants A Double-blind Placebo-controlled Randomization Research Study for Major Depression
Status:
WITHDRAWN
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
PI move
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Antidepressants are commonly prescribed and are effective for treating depression However they generally take 4-6 weeks for a therapeutic response This study is evaluating whether simultaneous treatment with thyroid hormone or pindolol can decrease the response time getting better faster in patients who are starting SSRI treatment
Detailed Description:
Major depression is an illness with substantial personal and economic morbidity Greenberg et al1993 and antidepressants are the cornerstone of treatment As antidepressants usually require 3-6 weeks of use before a response occurs an effective antidepressant acceleration strategy would reduce the time of onset for an effective antidepressant response This has significant clinical implications as it could lead to reduced symptom morbidity potentially reduce health care cost ie shorter hospital length of stay and improve functional capacity and quality of life
The goal of this study is to enhance our understanding of strategies that accelerate or produce a more rapid treatment response in depression This could lead to reduced symptom morbidity potentially reduce health care cost ie shorter hospital length of stay and improve functional capacity and quality of life
The study goals are 1 To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can accelerate the treatment response ie faster rate of improvement 2 To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can augment or enhance treatment response ie greater reduction in depressive symptoms at end of study phase adn 3 To assess whether gender influences the acceleration of augmentation response rate of liothyronine or pindolol
The goal of this study is to enhance our understanding of strategies that accelerate or produce a more rapid treatment response in depression This could lead to reduced symptom morbidity potentially reduce health care cost ie shorter hospital length of stay and improve functional capacity and quality of life
The study goals are 1 To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can accelerate the treatment response ie faster rate of improvement 2 To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can augment or enhance treatment response ie greater reduction in depressive symptoms at end of study phase adn 3 To assess whether gender influences the acceleration of augmentation response rate of liothyronine or pindolol
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None